Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bioxyne Ltd's chief executive officer steps down


Sunday, 1 Dec 2013 06:07pm EST 

Bioxyne Ltd:Says that subsequent to the execution of a non-binding heads of agreement (HOA) to sell its HI-164 Oral Vaccine project together with all of its intellectual properties (IP) to Mariposa Health Limited (MHL), Phillip Comans has stepped down as chief executive officer of the company.Says in the interim, operational matters would be managed by the chairman, Tony Ho and the CFO Jarrod White. 

Company Quote

0.019
-0.0010 -5.00%
19 Sep 2014